I read it the same way. The wording exactly was "...to raise funds for NeoCard biologics license application and commercialization following approval by the U.S. Food and Drug Administration."
To me that sounds like they are planning/almost already know the FDA will approve it and because of that they need money for commercialization i.e. marketing and selling the product.
I personally think they might do an offering AFTER the FDA meeting so they would be selling shares for something like $2.80 a share.